Liver cancer study: chemical and social risk factors
Part of Cancer, Digestive system clinical trials.
This study looks at how chemicals in our environment and life stress might be linked to liver cancer. It is for people with fatty liver disease caused by metabolism or alcohol, who are having a liver biopsy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of fatty liver disease caused by metabolism, alcohol, or both (called MASLD, ALD, or MetALD).
- You need a liver biopsy to check for cirrhosis (scarring) or for liver cancer (hepatocellular carcinoma).
- You have health insurance (social security).
- You are willing to sign a consent form to donate a small sample for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
This trial studies people with liver disease linked to alcohol use or metabolic syndrome (a cluster of conditions like weight gain and insulin resistance). It uses recent standard-of-care liver biopsy results to better understand these chronic liver problems and how they relate to cancer risk.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
This study looks at factors that predict liver cancer and the need for a liver transplant in people with a liver condition called MASLD (metabolic dysfunction-associated steatotic liver disease). The goal is to better understand the disease and improve care.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
Hear when a new Cirrhoses, Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.